Clobromazolam, medetomidine and six more go before WHO's drug committee in October; FDA takes comments until September 3

FDA, acting for HHS, is asking for public comment through September 3, 2026 (docket FDA-2026-N-9208) on eight drug substances that will come before the World Health Organization's Expert Committee on Drug Dependence (ECDD) at its 49th meeting in Geneva, October 19–22, 2026.

This is the international scheduling track under the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances, not US scheduling [1]. The ECDD may recommend that one or more of these substances be brought under international control; the US has taken no position on any of them, and if it does take a position later, that will be announced in a separate Federal Register notice first [1]. Nothing in this notice changes what is legal to possess, sell, or manufacture in the United States today.

Their US status varies, and none of it is set by this document. Etomethazene has been temporarily in Schedule I under the Controlled Substances Act since October 15, 2025 [1]. Cychlorphine and spirochlorphine are not yet controlled, but DEA published a notice of intent on July 1, 2026 to place both temporarily in Schedule I, and that order has not yet issued [1]. Clobromazolam, desalkylgidazepam, and ethylbromazolam are not controlled under the CSA [1]. Etomidate is FDA-approved for anesthesia and not controlled under the CSA [1]. Medetomidine is veterinary-only and federally uncontrolled, though Pennsylvania placed it in Schedule III in 2026 [1].

Three facts from the notice are worth knowing if you're handling any of these now, regardless of what WHO or DEA eventually decide. Desalkylgidazepam has an average elimination half-life around 86 hours [1]. Medetomidine is estimated at 100 to 200 times the potency of xylazine [1]. Ethylbromazolam has frequently been found in counterfeit tablets misrepresented as diazepam, alprazolam, or clonazepam [1]. Cychlorphine tested roughly ten times more potent than fentanyl in vitro [1].

The comment period runs to September 3, 2026. ECDD meets in Geneva October 19–22; any resulting US position will get its own Federal Register notice before it goes anywhere [1].

References

1. International Drug Scheduling: Single Convention on Narcotic Drugs, Convention on Psychotropic Substances; Clobromazolam (phenazolam), Cychlorphine (N-propionitrile chlorphine), etc. — Federal Register (public inspection)